ArticleEye (London, England)2026
Choroidal medium-large vascular index: a novel OCTA biomarker for assessing activity in thyroid eye disease.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesTo elucidate the fundus changes in active and inactive thyroid eye disease (TED), as well as to establish reliable fundus indicators for assessing disease activity.
methodsIn this retrospective cross-sectional study, 30 active TED patients (50 eyes), 26 inactive TED patients (47 eyes) and 26 healthy controls (50 eyes) were enroled. All participants underwent macular optical coherence tomography (OCT) and angiography. Retinal thickness (RT), choroidal thickness (CT), retinal superficial vascular index (RSVI), retinal deep vascular index (RDVI), as well as choroidal capillary vascular index (CCVI) and choroidal medium-large vascular index (CMLVI) were automatically quantified. The diagnostic performance of these metrics for distinguishing active and inactive TED was evaluated through receiver operating characteristic (ROC) curve analysis.
resultsThe subfoveal and parafoveal CT was significantly greater in active TED group compared to both the inactive group and control group (P < 0.05). Among vascular indices, the CMLVI in both the subfoveal and parafoveal zone was significantly higher in active TED patients than in those with inactive disease or controls (P < 0.001). However, no significant differences were observed regarding RT, retinal vascular indices, or the CCVI between active and inactive groups. ROC analysis indicated that CMLVI at fovea exhibited superior activity diagnostic efficacy (AUC = 0.811).
conclusionsCompared with inactive TED patients, active TED patients exhibit more prominent choroidal changes than retinal alterations. In addition, the variation in choroidal vessels is more significant than that in thickness. The subfoveal CMLVI is identified as an optimal, objective, and reliable OCTA biomarker for distinguishing active from inactive TED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.